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Glycated and carboxy-methylated proteins do not directly
activate human vascular smooth muscle cells.
Background. Advanced glycation end products (AGEs) ac-
cumulate in patients with diabetes, particularly at sites of vascu-
lar damage and within atherosclerotic lesions, but whether they
have direct actions on vascular smooth muscle cells (VSMCs)
is controversial.
Methods. AGEs were constructed and characterized by pro-
tein content, level of modification, fluorescence, and molecular
size. Human VSMCs were derived from different vascular beds.
Glucose consumption, de novo protein synthesis, and proteogly-
can biosynthesis were measured using a colorimetric assay and
metabolic radiolabeling. Receptor for AGEs (RAGE) expres-
sion was assessed by real-time reverse transcription-polymerase
chain reaction (RT-PCR) and Western blot.
Results. Treatment with AGEs under low or high glucose con-
ditions showed no change in cellular glucose consumption or in
cellular protein synthesis under low glucose conditions. Treat-
ment of VSMCs with Ne-(carboxymethyl)lysine in the pres-
ence of low glucose increased [35S]-sulfate incorporation into
secreted proteoglycans by 72% (P < 0.001) and 67% (P <
0.001); however, the control proteins also increased [35S]-sulfate
incorporation into proteoglycans by 56% (P < 0.01), with sim-
ilar effects observed under high glucose conditions. Human
VSMCs showed no difference in response to glycated and non-
glycated protein. Protein and gene expression of RAGE in
VSMC was approximately 50-fold lower compared to HMEC-1
and U937 cells, consistent with the immunohistochemical stain-
ing of RAGE in vivo.
Conclusion. VSMCs show very low levels of RAGE expres-
sion; thus, activation of VSMCs by AGEs does not occur. In
diabetes, RAGE expression in VSM may increase to the ex-
tent that it becomes activated by AGEs in a manner that would
contribute to the process of atherosclerosis.
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Advanced glycation end products (AGEs) represent
a heterogenous group of carbohydrate-protein adducts
that have been recently implicated in the development
and progression of atherosclerosis [1, 2]. Increasing age,
dyslipidemia, oxidative stress, and hyperglycemia result
in the enhanced accumulation of AGEs, particularly at
sites of vascular injury [1, 2]. Inhibition of AGE accu-
mulation is able to attenuate accelerated atherosclerosis
associated with diabetes, without restoring glucose levels
to the normal range [3, 4]. This suggests that AGEs are
key mediators of vascular injury in diabetes. However,
the mechanisms by which AGEs promote atherosclero-
sis have not been elucidated.
Many of the deleterious actions of AGEs are thought
to be mediated by activation of multispecific receptors
and binding proteins [1, 5]. In particular, the receptor
for AGEs (RAGE) is thought to play an important role
in the induction of inflammation, proliferation, and fi-
brogenesis following exposure to AGEs. RAGEs have
been identified in human atherosclerotic plaques [6–9]
and are up-regulated in atherosclerotic lesions associated
with experimental diabetes [5, 10]. Furthermore, the use
of soluble RAGE to competitively block activation of tis-
sue associated RAGE results in reduced atherosclerotic
lesion formation [5].
The cellular target for action(s) of vascular AGEs also
remains to be established. There is little or no informa-
tion on the direct effects of AGEs on human VSMCs.
One report has shown that RAGE ligands do not in-
duce proliferation of human vascular smooth muscle cells
(VSMCs) [11]. The lack of AGE response on vascular
smooth muscle is surprising in view of the cental role of
this tissue in atherogenesis [12]. This is a very important
point in terms of identifying the role of AGEs in human
atherosclerosis and, subsequently, the opportunities to in-
tervene to attenuate the atherosclerotic process. We have
addressed this question in our established model of non-
transformed human vascular smooth muscle cells derived
2756
Ballinger et al: Protein glycation and smooth muscle activation 2757
from human vessels [13]. We have evaluated the direct
effects of various AGEs on three properties of VSMCs,
namely, glucose utilization [14], de novo protein synthesis
[15], and enhanced proteoglycan biosynthesis including
glycosaminoglycan elongation [16], which represents in-
dicators of cellular activation, a hypertrophic response,
and an atherogenic response, respectively. We have char-
acterized the AGEs and assessed the levels of RAGE
expression in VSMCs.
METHODS
Reagents
All chemicals were of the highest grade and obtained
from Sigma Chemicals (St. Louis, MO, USA) unless oth-
erwise stated. Goat anti-RAGE polyclonal immunoglob-
ulin G (IgG) was from Chemicon (Temecula, CA, USA).
Avidin-biotin-peroxidase complex was from Vector Lab-
oratories (Burlingame, CA, USA). Anti-goat IgG labeled
with horseradish peroxidase (HRP) was from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Fetal bovine
serum (FBS) was from CSL (Melbourne, Australia).
AGE construction and characterization
Bovine serum albumin (BSA)-AGE was prepared
by long-term incubation (60 days) of BSA fraction V
(1 mmol/L) with D-glucose (1 mol/L) in sodium phos-
phate buffer, under sterile aerobic conditions at 37◦C
[17]. Ne-(carboxymethyl)lysine (CML) with two degrees
of glycation were constructed by sterile incubation of
glyoxylic acid (1 mg, 10 mg) and sodium cyanoborohy-
dride (2 mg, 19.8 mg) dissolved in 0.4 mol/L sodium
phosphate buffer, with BSA (176 mg) for 24 hours,
in a total reaction volume of 1 mL [18]. Control pro-
teins were prepared as described for BSA-AGE with the
omission of D-glucose, and CML with the omission of
glyoxylic acid and sodium cyanoborohydride. Extensive
dialysis of preparations was performed postincubation
against Dulbecco’s phosphate-buffered saline (PBS) to
remove non-protein bound entities. The BSA-AGE and
CML preparations were assessed for protein content and
free amino groups using the BCA assay and the TNBS
assay [19], respectively. The fluorescent properties of
BSA-AGE, CML, and protein controls (1 mg/mL) were
measured with excitation at 350 nm, emission 360–500 nm
on a scanning spectrofluorometer (Spex Industries, Edi-
son, NJ, USA). The size and derivative formation of
BSA-AGE, CML, and protein controls was assessed on
a 4% to 13% linear gradient sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE).
Cell culture
Discarded segments of the internal mammary artery
(IMA), radial artery (RA), and saphenous vein (SV)
were obtained from the Alfred Hospital Cardiac Surgery
Unit (Alfred Hospital, Melbourne, Australia), with at
least 2 different patients with each vessel type. The Al-
fred Hospital Human Ethics Committee approved the
acquisition of the tissue. Human vascular smooth mus-
cle cell cultures were established using the explant tech-
nique as previously described [13], stained positive for
smooth muscle a-actin, and showed characteristic “hills
and valleys” by phase contrast microscopy [20]. The me-
dia utilized for cell growth was low (5 mmol/L) glu-
cose Dulbecco’s modified Eagle’s medium (DMEM)
with 10% FBS, and for experiments both low and high
(25 mmol/L) glucose DMEM with 10% FBS were used.
All experiments were conducted on cells from passage
8 to 17 in 24 well plates (Becton Dickinson, Franklin
Lakes, NJ, USA). Prior to all experiments cells were ren-
dered quiescent by incubation in low glucose DMEM,
0.1% FBS for 48 hours unless otherwise stated. U937
cells were obtained from Dr V.T. Tkachuk, Cardiol-
ogy Research Center, Moscow, Russia. U937 cells were
maintained in RPMI, 10% heat-inactivated serum con-
taining antibiotics at 37◦C. U937 cells were rendered
quiescent in RPMI zero serum for 24 hours prior to treat-
ment. Human microvascular endothelial cells (HMEC-
1) were obtained from Dr. Karlheinz Peter, Baker
Heart Research Institute, Melbourne, Australia. HMEC-
1 cells were maintained in MCDB131 media containing
10% FBS and supplemented with epidermal growth
factor (1 lg/100mL), hydrocortisone (1 lg/500mL), L-
glutamine, and antibiotics.
Glucose utilization
Aerobic glycolysis is the major pathway of glucose uti-
lization in vascular smooth muscle [21]. Glucose con-
sumption, which is coupled with lactate production, was
measured as a general indicator of cellular activation [14].
Confluent and quiescent VSMCs were treated with BSA-
AGE (1-100 lg/mL), TGF-b1 (2 ng/mL), short-term and
long-term BSA controls (30 lg/mL each), CML least
and most glycated (30, 100 lg/mL), CML most glycated
(100 lg/mL), with TGF-b1 (2 ng/mL) and incubated at
37◦C for 24 hours. Treatments were performed in the pres-
ence of low (5 mmol/L) and high (25 mmol/L) glucose
medium containing 0.1% FBS. To determine cellular glu-
cose consumption, glucose concentrations in the medium
were determined pre- and post-treatment using the pho-
tometric hexokinase/NADPH reaction, and lactate was
analyzed using a colorimetric reaction with lactate oxi-
dase and peroxidase. Reaction end points were detected
using a COBAS FARA Analytical System (Roche, Basel,
Switzerland). Cells from each well were collected after
trypsin treatment and counted on a Z2 Particle & Size An-
alyzer (Coulter Corp., Miami, FL, USA). U937 cells were
treated with BSA-AGE (100 lg/mL) or long-term BSA
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control (100 lg/mL) in RPMI zero serum for 24 hours
at 37◦C and glucose utilization assessed as described
above.
De novo protein synthesis
Activation of cellular protein synthesis may precede an
increase in DNA synthesis in vascular cells treated with
growth stimuli [15]. To investigate the synthesis of new
proteins, confluent human VSMC on 24-well plates were
rendered quiescent and treated with CML least and most
glycated (100 lg/mL), BSA-AGE (100 lg/mL), short-
term and long-term BSA controls (100 lg/mL each),
TGF-b1 (2 ng/mL), and BSA-AGE (100 lg/mL) with
TGF-b1 (2 ng/mL) in low and high glucose DMEM,
0.1% FBS. Treated cells were incubated for 16 hours at
37◦C. The treatment medium was aspirated and replaced
with low glucose DMEM, 0.1% FBS (1 mL), followed
by the addition of 10 lCi/mL [35S]-methionine/cysteine
(ICN Biomedicals, Irvine, CA, USA) for 4 hours at 37◦C.
The medium was aspirated and the cells were washed
three times with PBS followed by incubation with 10%
trichloroacetic acid (TCA) for 30 minutes on ice to pre-
cipitate the proteins. The TCA was aspirated dry followed
by a second treatment with TCA. To solubilize the pro-
tein, 0.1% SDS in 0.1 mol/L NaOH was added to each
well for 30 minutes at 37◦C, with occasional agitation.
Protein solutions were neutralized with 1 mol/L acetic
acid (100 lL) and counted for [35S] in a liquid scintilla-
tion counter (Packard, Meriden, CT, USA).
Proteoglycan biosynthesis
Proteoglycan biosynthesis was evaluated as a mea-
sure of a specific atherogenic response [22, 23]. TGF-b1
stimulates proteoglycan synthesis in vascular SMCs [22,
24]. Human VSMCs were grown to confluence on 24-
well plates and serum deprived for 48 hours. Cells were
treated with TGF-b1 (1 ng/mL), short-term BSA control
(100 lg/mL), CML least and most glycated (100 lg/mL).
Vascular SMCs were metabolically labeled with [35S]-
sulfate (100 lCi/mL) for 24 hours at 37◦C. Identically
treated parallel plates were established without radio-
label to count cells. The medium was collected from
each well and the cell layer harvested as previously de-
scribed [25]. To quantitate total proteoglycan biosynthe-
sis an aliquot (50 lL) of the medium and cell samples
were applied to individual sections of chromatography
paper (Whatman 3MM; Maidstone, UK). The paper was
dried and extensively washed in a solution containing 1%
cetylpyridinium chloride (CPC), and 50 mmol/L NaCl.
After drying and addition of scintillation fluid (10 mL),
individual papers were counted for [35S] in a liquid scin-
tillation counter.
Real-time quantitative RT-PCR for RAGE
VSMCs were harvested, homogenized, and total RNA
was isolated using Ultra-Turrax (Janke & Kunkel IKA,
Labortechnik, Germany) in TRIZOL (Life Technologies,
Inc., Gaithersburg, MD, USA). cDNA was synthesized
with a reverse transcriptase reaction using a standard
technique (SuperscriptTM First Strand Synthesis System
for RT-PCR; Life Technologies, Inc.) as previously de-
scribed [26]. To assess genomic DNA contamination, con-
trols without reverse transcriptase were included.
Real-time reverse transcription-polymerase chain re-
action (RT-PCR) was used for the quantitative determi-
nation of mRNA. Briefly, gene specific 5′-oligonucleotide
corresponding to the human RAGE (5′-AGGAATGGA
AAGGAGACCAAGTC), RAGE 3′-oligonucleotide
primer (5′-CGTGAGTTCAGAGGCAGAATCTAC),
and RAGE probe (FAM5′-TCTACCAGATTCCTGG
GAAGCCAGAAATTG-TAMRA) were designed us-
ing the software program ‘Primer Express’ (PE Applied
Biosystems, Foster City, CA, USA), and real-time PCR
was carried out as previously described [26]. The level of
expression of 18S was used as the endogenous control
to ensure equal starting amounts of cDNA. Expression
of RAGE gene by SMCs derived from the IMA was
used as the calibrator with a given value of 1, with other
groups compared with this calibrator.
Western blotting for RAGE
To investigate the presence and size of immunoreactive
RAGE proteins in whole cell lysates, a Western blot was
performed. Human VSMCs were grown to confluence on
60 mm plates, serum deprived for 24 hours, rinsed with
PBS, then harvested by gentle scraping after application
of a buffer containing Triton X-100 (1%), NaCl (5 mol/L),
TRIS pH 7.5 (1 mol/L), EDTA (500 mmol/L), EGTA
pH 9.0 (250 lmol/L), NP-40 (0.5%), PMSF (40 mmol/L),
leupeptin (1%), and pepstatin (1%). The lysate was
sonicated, centrifuged (1000 rpm, 10 min, 4◦C), the super-
natant collected, and protein content determined using
the BCA assay. Protein (50 lg) was separated on a 10%
SDS-PAGE and molecular weight markers (Invitrogen
Life Technologies, Carlsbad, CA, USA) were used to in-
dicate size. Proteins were transferred electrophoretically
onto a polyvinylidene fluoride (PVDF) membrane and
nonspecific binding sites blocked by immersion of mem-
brane into 5% skim milk (1 hour). The membrane was
incubated with goat anti-RAGE polyclonal IgG (1:1000)
at 4◦C overnight. Following washing, the secondary an-
tibody, anti-goat IgG labeled with HRP (Santa Cruz
Biotechnology), was applied at 1:2000 for 1 hour. The
Chemiluminescence Reagent Plus system (NEN Life Sci-
ences, Boston, MA, USA) was used to detect sites of pri-
mary antibody binding.
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Fig. 1. BSA-AGE but not Ne-(carboxymethyl)lysine (CML) shows flu-
orescent properties. AGEs were prepared as described in Methods and
assessed for fluorescence at excitation k350 nm and emission k390–
490 nm. Buffer (), short-term BSA control (), long-term BSA control
(◦), BSA-AGE (•), and most glycated CML (). BSA-AGE exhibited
fluorescence, while the most glycated CML and controls did not show
this property. Each trace was determined three times or more.
In vivo localization of vascular RAGE
by immunohistochemistry
Representative frozen sections of human IMA were
prepared on a cryostat, fixed in acetone, and stained
to identify and localize RAGE by immunohistochem-
istry. Nonspecific binding was blocked with 10% normal
horse serum. The primary antibody, goat anti-RAGE IgG
(1:400), was applied followed by detection with an avidin-
biotin-peroxidase complex (Vector Laboratories) in con-
junction with 3,3′-diaminobenzidine (Dako, Glostrup,
Denmark) for color development. Controls included a
positive rat lung sample (which showed strong positive
staining only in the presence of the primary antibody) and
a negative control where the primary antibody was sub-
stituted with goat IgG. Counterstaining was performed
with hematoxylin.
Statistical analyses
Data are presented as the mean and standard error of
the mean. Data were analyzed using a one-way analysis of
variance (ANOVA). Results were considered significant
when the P value was less than 0.05, 0.01, and 0.001, as
indicated in individual figures.
RESULTS
Characterization of AGEs
The constructed AGEs, BSA-AGE, and CMLs were
characterized for protein content and free amino groups.
BSA-AGE had 86% less free amino groups than BSA
control protein, indicating significant glycation had oc-
curred. Least and most glycated CML preparations
98
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Fig. 2. Electrophoretic migration of AGEs by SDS-PAGE. AGEs were
prepared as described in Methods and separated on a 4-13% SDS-
PAGE followed by staining with 0.025% Coomassie Blue. BSA-AGE
and most glycated CML showed an increase in size relative to the BSA
control proteins. Gel represents two separate experiments.
showed a 21% and 73% reduction, respectively, in the
available amino groups. Spectrofluorimetric analyses of
the AGEs revealed BSA-AGE to exhibit fluorescence,
but the BSA control protein and the least and most gly-
cated CML did not exhibit fluorescence (Fig. 1). The
BSA-AGE showed a reduction in the electrophoretic
migration, indicating an increase in size relative to the
long-term BSA control (Fig. 2). The most glycated CML
showed reduced electrophoretic migration, indicating an
increase in size relative to the short-term BSA control
(Fig. 2).
Effect of AGEs on cellular glucose utilization
Vascular SMCs utilize glucose in glycolysis to produce
ATP when ATP is consumed during any cellular activa-
tion. To demonstrate that an alteration in glucose uti-
lization is an appropriate indicator of cellular activation,
VSMCs were treated with TGF-b1, a known activator
and atherogenic stimulus for SMCs. As expected, human
VSMCs treated with TGF-b1 (2 ng/mL) showed a 1.9-fold
(P < 0.001) and 2.1-fold (P < 0.001) increase in cellular
glucose utilization under low and high glucose conditions,
respectively (Fig. 3A and B). Human VSMCs treated with
BSA-AGE (1-100 lg/mL) showed no change in glucose
utilization relative to the long-term BSA control regard-
less of whether the treatment was in low or high glu-
cose medium (Fig. 3A and B). Treatment of VSMCs with
least and most glycated CMLs (30-100 lg/mL) showed
no change in glucose utilization relative to the short-term
BSA control under both low and high glucose conditions
(Fig. 4A and B). Cotreatment of VSMCs with TGF-b1
and CML (100 lg/mL) did not alter cellular glucose con-
sumption compared to cells treated with TGF-b1 alone
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Fig. 3. BSA-AGE treatment of VSMCs does not alter cellular glucose
utilization. Human VSMCs were treated with DMEM containing 0.1%
serum (Con), TGF-b1 (2 ng/mL), long-term BSA control (BSA Con,
30 lg/mL), or BSA-AGE (1-100 lg/mL) under (A) low (5 mmol/L) or
(B) high (25 mmol/L) glucose conditions. Results are a mean ± SEM
from three separate experiments. Significance indicated relative to basal
control (∗∗∗P < 0.001).
(Fig. 4A and B). Agonist effects on glucose consump-
tion were mirrored as expected by simultaneous determi-
nation of lactate production as the product of glycolysis
(data not shown).
Effect of AGEs on de novo protein synthesis
The de novo protein synthesis assay was another poten-
tial measure of general cellular responsiveness to AGE
treatment. Under low glucose conditions, cellular re-
sponse to CML least glycated and CML most glycated
were increased relative to the control by 25% (P < 0.01)
and 28% (P < 0.01), respectively, but was not changed
relative to the short-term BSA control (Fig. 5A). The
increase in de novo protein synthesis under low glu-
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Fig. 4. CML treatment of VSMCs does not alter cellular glucose uti-
lization. Human VSMCs were treated with DMEM containing 0.1%
FBS (Con), TGF-b1 (2 ng/mL), short-term BSA control (BSA Con,
30 lg/mL), CML least glycated (30, 100 lg/mL) or CML most glycated
(30, 100 lg/mL), and CML (100 lg/mL) most glycated with TGF-b1
(2 ng/mL) under (A) low (5 mmol/L) or (B) high (25 mmol/L) glucose
conditions. Results are mean ± SEM from two separate experiments.
Significance indicated relative to basal control (∗P < 0.05, ∗∗∗P < 0.001).
cose conditions was not due to glycation of proteins. Un-
der high glucose conditions, VSMCs treated with AGEs
showed no change in de novo protein synthesis compared
to untreated cells (Fig. 5B).
Effect of AGEs on proteoglycan biosynthesis
Growth factor activation of VSMCs leads to stimu-
lation of proteoglycan synthesis and, specifically, elon-
gation of GAGs and increased binding to low-density
lipoprotein (LDL) [27]. Treatment of VSMCs with TGF-
b1 (1 ng/mL) increased [35S]-sulfate incorporation into
proteoglycans by 80% (P < 0.001) and 164% (P < 0.001)
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Fig. 5. Treatment of VSMCs with CMLs increases de novo protein syn-
thesis relative to basal but not relative to BSA control under low glu-
cose conditions. Human VSMCs were treated with DMEM containing
0.1% FBS (Con), TGF-b1 (2 ng/mL), long-term BSA control (BSA Con
LT, 30 lg/mL), BSA-AGE (100 lg/mL), short-term BSA control (BSA
Con ST, 30 lg/mL), CML least glycated (100 lg/mL) or CML most gly-
cated (100 lg/mL) under (A) low (5 mmol/L) or (B) high (25 mmol/L)
glucose conditions. Cells were metabolically labeled with [35S]-met/cys
(10 lCi/mL) for 4 hours prior to analyzing de novo protein. Results are
a mean ± SEM from three separate experiments. Significance indicated
relative to basal control (∗P < 0.05, ∗∗P < 0.01).
under low and high glucose conditions, respectively, com-
pared to untreated cells (Fig. 6A and B) [22]. Human
VSMCs treated with the short-term BSA control showed
an increase in [35S]-sulfate incorporation into proteogly-
cans by 56% (P < 0.01) and 69% (P < 0.001) under low
and high glucose conditions, respectively, compared to
untreated cells (Fig. 6A and B). Treatment of cells with
least and most glycated CMLs showed that [35S]-sulfate
incorporation into proteoglycans was increased by 72%
(P < 0.001) and 67% (P < 0.001), respectively, relative to
the control under low glucose conditions. However, the
extent of stimulation with the CMLs was not different
from the short-term BSA control (Fig. 6A). Similar ef-
fects of CML treatment on SMC proteoglycan synthesis
were observed under high glucose conditions (Fig. 6B).
The cell-associated proteoglycans were assessed follow-
ing treatment with CMLs and the results reflected and
confirmed those observed in the media samples (data not
shown).
Vascular SMCs treated with CMLs showed no change
in the electrophoretic migration of radiolabeled proteo-
glycans, biglycan and decorin, by SDS-PAGE whether the
treatment was under low or high glucose conditions, indi-
cating that the increase in [35S]-sulfate incorporation into
proteoglycans was not associated with a growth factor–
like increase in glycosaminoglycan length (Fig. 6C and D).
Gene and protein expression of RAGE in human VSMCs
and IMA sections
Gene and protein expression of the full-length tissue
RAGE was assessed by RT-PCR and Western blotting,
respectively (Fig. 7A and B). Due to the low level of ex-
pression of RAGE in cells derived from the IMA we also
determined the expression of RAGE in cells derived from
two distinct vessels, the saphenous vein and radial arter-
ies [28]. There was little variability in RAGE expression
between the VSMC types despite their different vascu-
lar sites of derivation. The constitutive level of expres-
sion in the three human VSMC types was markedly less
than seen in either U937 monocytes or human endothe-
lial cells. Overall expression of the RAGE gene was over
200-fold lower in VSMCs when compared to monocytes
or HMEC-1 cells. Protein expression of RAGE was at
least 50-fold lower in VSMCs compared to monocytes
and human endothelial cells.
To confirm that the difference in RAGE expression is
manifest as a functional difference in signaling we mea-
sured the effect of BSA-AGE on glucose consumption
by U937 cells by identical methods to those used ear-
lier for the consumption of glucose in vascular smooth
muscle cells. Treatment of U937 cells with BSA-AGE
(100 lg/mL) increased glucose consumption by 53.1 ±
8.5% (P < 0.001) relative to control (Fig. 7C).
In vascular sections obtained from human IMA, im-
munohistochemical staining for RAGE was strongest in
the endothelium and focal sites within the intima. Only
scanty and diffuse staining was observed in VSMCs in the
media, with an overall level of staining barely above back-
ground (Fig. 8A). The IMA section that was not treated
with the primary antibody showed negative staining for
RAGE (Fig. 8B).
DISCUSSION
AGEs are strongly implicated in the etiology of the
accelerated atherosclerosis that accompanies diabetes
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Fig. 6. Treatment of VSMCs with CMLs in-
creases [35S]-sulfate incorporation into pro-
teoglycans relative to basal but not relative
to BSA control. Human VSMCs were treated
with DMEM containing 0.1% FBS (Con),
TGF-b1 (1 ng/mL), short-term BSA con-
trol (BSA Con, 100 lg/mL), CML least gly-
cated (100 lg/mL) or CML most glycated
(100 lg/mL) under (A) low (5 mmol/L) or (B)
high (25 mmol/L) glucose conditions. Cells
were metabolically labeled with [35S]-sulfate
(100 lCi/mL) for 24 hours prior to analysis
of secreted proteoglycans by the CPC pre-
cipitation assay. Results are a mean ± SEM
from three separate experiments. Significance
indicated relative to basal control (∗∗P <
0.01, ∗∗∗P < 0.001). Radiolabeled proteogly-
cans from SMCs treated with short-term BSA
control (BSA-Con, 30 lg/mL), CML most
glycated (100 lg/mL), CML least glycated
(100 lg/mL), or DMEM containing 0.1% FBS
(Con) under (C) low (5 mmol/L) or (D) high
(25 mmol/L) glucose conditions, were sepa-
rated by SDS-PAGE.
[5]. Vascular SMCs are the central cellular participant
in atherosclerosis but the demonstration of atherogenic
responses by VSMC to AGEs is lacking [11]. We pre-
pared and characterized several AGEs and examined
their acute effects on the responses of human VSMC,
which would indicate cellular activation and a role in
atherogenesis; the presence of RAGE on the chosen cell
type was also determined by both immunohistochemistry
and Western blotting. However, the multiple glycated
proteins used in this study either did not have any effect
on VSMCs, nor did they stimulate any cellular response
over and above the nonglycated protein control. We fur-
ther showed that VSMCs both in vitro and in vivo show
very low levels of RAGE expression and, thus, activation
of VSM by AGEs may not occur. We also confirmed that
AGE treatment of U937 cells, which express a high level
of RAGE, resulted in activation of cellular metabolism
assessed as increased glucose utilization.
The clinical manifestations of atherosclerosis lead-
ing to cardiovascular disease and acute clinical syn-
dromes actually have three major components. First, the
lipid-dependent binding and retention of atherogenic
lipoproteins by vascular extracellular matrix molecules,
including proteoglycans [22, 29, 30]; second, the inflam-
matory process of monocyte adhesion to the vessel wall
and subsequent macrophage proliferation [12, 31]. These
major events come together to generate lipid laden foam
cells that develop into the complex lesions of atheroscle-
rosis. The third major process is the thrombotic occlusion
accompanying plaque rupture, which leads to the acute
clinical syndrome [32]. There is now clear evidence for
the involvement of AGEs and their receptors at critical
but undefined points in the process [6].
It has previously been suggested that chronic low
level activation of vascular AGE receptors by circulating
AGEs and locally derived AGE modifications leads to
vascular dysfunction and atherogenesis [33]. We hypoth-
esize that one factor determining the nonresponsiveness
of normal human VSMCs to the effects of AGEs may be
the low level of constitutive expression of AGE recep-
tors and, in particular, RAGE. In our studies the level
of expression of RAGE both in vitro and in vivo was
considerably lower than observed in endothelial cells or
monocytes. However, in response to metabolic states such
as diabetes, dyslipidemia, uremia, and aging, the expres-
sion of RAGE may be enhanced, possibly due to a posi-
tive feedback stimulus from high levels of AGEs in these
conditions [5]. Certainly, at sites of diabetes-associated
vascular injury, there is a high level of RAGE expres-
sion that colocalizes with AGEs and other atherogenic
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Fig. 7. RAGE gene and protein expression correlates with AGE mediated cellular activation in vascular cells. Data show results from (A) real
time quantitative RT-PCR and (B) Western blotting for RAGE mRNA and protein, respectively. (A) Three lines of SMCs (IMA, RA, and SV),
U937 monocytes/macrophages (Mu), and HMEC-1 cells were analyzed for RAGE expression. (B) For Western blotting a positive control of lung
tissue is shown. Immunoreactive RAGE proteins in the 40 to 60 kD size range were detected. IMA, internal mammary artery; SVC, saphenous
vein cells; RA, radial artery; Mu, U937 monocytes/macrophages. (C) U937 cells were treated with RPMI zero serum and BSA-AGE (100 lg/mL)
or long-term BSA control (BSA Con, 100 lg/mL) for 24 hours at 37◦C. Results are mean ± SEM from three separate experiments conducted in
triplicate. Significance indicated relative to basal control (∗∗P < 0.01, ∗∗∗P < 0.001).
mediators (e.g., CTGF [34] and MCP-1 [35]) that have
been implicated in the development and progression of
human and animal atherosclerotic plaques [10, 36]. Thus,
factors may operate in vivo in the presence of diabetes to
up-regulate RAGE, and this generates VSMCs that can
show atherogenic responses to AGEs. It will be impor-
tant to determine the factors that can up-regulate RAGE
expression.
It is possible that the short-term nature of our studies
failed to detect a change that may have been observed at
later time points. For example, Chang et al have shown
that oxidized LDL stimulates proteoglycan biosynthesis
in VSMCs only after 72 hours of exposure [37]. However,
long duration experiments are not suited to cell culture
models since factors such as alterations in cell phenotype
[38] and nutrient depletion or secretory product accumu-
lation in the media may impact the results. Such exper-
iments may also reveal secondary effects, such as those
resulting from the release of growth factors like PDGF
[39] or TGF-b [40], which are known to mediate SMC
proliferation.
VSMC proliferation is thought to be consequent upon
activation of de novo protein synthesis and, thus, this lat-
ter assay was also used as an early marker of proliferation
in our experiments. The absence of activation of protein
synthesis strongly suggests that there would be no mito-
genic response. In addition, the experiments conducted in
the present report also had positive controls demonstrat-
ing that cellular activation is indeed possible. Exposure
to weak or partially competent agonists or growth factors
may produce short-term responses such as an increase
in intracellular pH [41] that do not manifest in cellular
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Fig. 8. Immunohistochemical staining for RAGE in human vascular
rings. (A) Frozen sections of human IMA were immunohistochemically
stained with goat anti-RAGE IgG (1:400). (B) A negative control of the
human IMA section where the primary antibody was substituted with
goat IgG.
responses in the absence of further stimulation. We did
not evaluate very short-term signaling responses such as
an increase in NF-jB [5] because our aim was to deter-
mine if AGEs could act as bona fide agonists capable of
generating full atherogenic cellular responses.
CONCLUSION
Our data do not impact on the role or importance of
AGEs in atherogenesis based on the lack of AGE stimu-
lation of VSMCs due to the very low expression of RAGE
in these cells and tissues. Insofar as the role of VSMCs is
concerned, factors which may activate RAGE expression
on VSMCs may draw these cells into the atherosclerotic
cascade. The high-level RAGE expression in endothelial
cells and macrophages both in vitro and in vivo, together
with their known responsiveness to physiologic AGEs,
also implicates these cells as possible key intermediates
between AGE accumulation and VSMC activation. Iden-
tifying and clarifying these processes as they occur in the
different settings of atherosclerosis is essential for un-
derstanding and, in the long-term, ameliorating human
atherosclerosis. Such findings will impact the likely path-
way to therapeutic agents capable of interfering in this
signaling process and preventing macrovascular disease
in diabetes.
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